NFKB1 and systemic lupus erythematosus: The use of monoclonal antibodies that inhibit NF-κB effector molecules such as IFNs, IL-6, IL-17, IL-23, and IP-10, which are implicated in lupus nephritis, is another area of possible precision treatment [28], which has led to the study and use of Anifrolumab, a FNAR1 antagonist, in SLE treatment.